Memantine Hydrochloride (HCl)

DRUG3 trials

Sponsors

Forest Laboratories

Conditions

Asperger SyndromeAsperger'sAsperger's DisorderAutismAutism Spectrum Disorder (ASD)Autism Spectrum DisordersAutistic DisorderPediatric Autism

Phase 2

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

TerminatedNCT01592773

Forest LaboratoriesAsperger's, Asperger's Disorder, Autism +4

Start: 2012-10-31End: 2014-03-31Updated: 2015-02-16

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

CompletedNCT01592786

Forest LaboratoriesAsperger's, Asperger's Disorder, Autism +4

Start: 2012-06-30End: 2013-08-31Updated: 2014-08-07

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

CompletedNCT01592747

Forest LaboratoriesAsperger's Disorder, Asperger Syndrome, Autism +3

Start: 2012-09-30End: 2013-10-31Updated: 2019-04-24

Related Papers

Memantine for the Treatment of Autism Spectrum Disorder: Overview of the Phase II Clinical Development Program (S42.009)

Neurology2014-04-08